Comparison of alterations of chromosome 17 in carcinoma of the ovary and of the breast

Virchows Archiv

Volumn 434, Issue 6, 1999, Pages 517-522

  Caduff, Rosmarie F ^a   Svoboda Newman, Suzette M ^b   Ferguson, Amy W ^c   Frank, Thomas S ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Utah   (United States)

Author keywords

Breast; Carcinoma; Chromosome 17; Loss of heterozygosity; Ovary

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; BREAST CARCINOMA; CHROMOSOME 17; CHROMOSOME 17Q; CHROMOSOME ABERRATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, BRCA1; HUMANS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033006248     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050377     Document Type: Article

References (29)

1. 1. Aberle H, Bierkamp C, Torchard D, Serova O, Wagner T, Natt E, Wirsching J, Heidkamper C, Montagna M, Lynch HT, Lenoir GM, Scherer G, Fuenteun J, Kemler R (1995) The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. Proc Natl Acad Sci U S A 92:6384-6388
2. 2. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974-979
3. 3. Banks L, Matlashewski G, Crawford L (1986) Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529-534
4. 4. Barbareschi M, Leonardi E, Mauri F, Serio G, Dalla Palma P (1992) p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98:408-418
5. 5. Bhargava V, Thor A, Deng G, Ljung BM, Moore DH, Waldman F, Benz C, Goodson W, Mayall B, Chew K, Smith HS (1994) The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 3:361-368
6. 6. Cropp CS, Champeme M-H, Lidereau R, Callahan R (1993) Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequenty deleted. Cancer Res 53:5617-5619
7. 7. Cropp CS, Nevanlinna HA, Pyrhönen S, Stenman UH, Salmikangas P, Albertsen H, White R, Callahan R (1994) Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Res 54:2548-2551
8. 8. De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Roels H (1989) The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44:969-974
9. 9. Frank TS, Bartos RE, Haefner HK, Roberts JK, Wilson MD, Hubbell GP (1994) Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma. Mod Pathol 7:3-8
10. 10. Frank TS, Svoboda-Newman SM, Hsi ED (1996) Comparison of methods for extracting DNA from formalin-fixed paraffin sections for non-isotopic PCR. Diagn Mol Pathol 5:220-224
11. 11. Friedman LS, Lynch ED, King M-C (1993) Two independent polymorphisms at the 17 beta-hydroxysteroid dehydrogenase (EDH17B) gene (17q21). Hum Mol Genet 2:821
12. 12. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122
13. 13. Godwin AK, Vanderveer L, Schultz DC, Lynch HT, Altomare DA, Buetow KH, Daly M, Getts LA, Masny A, Rosenblum N, Hogan M, Ozols RF, Hamilton TC (1994) A common region of deletion on chromosome 17 in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 55:666-677
14. 14. Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leech V, Molyneux A, Berchuck A, Ponder BAJ, Bast RC (1993) A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53:1218-1221
15. 15. Kalikin LM, Qu X, Frank TS, Caduff RF, Svoboda SM, Law DJ, Petty EM (1996) Detailed deletion analysis of sporadic breast tumors defines an interstitial region of allelic loss on 17q25. Genes Chromosom Cancer 17:64-68
16. 16. Kalikin LM, Frank TS, Svoboda-Newman SM, Wetzel JC, Cooney KA, Odocha IN, Petty EM (1997) A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. Oncogene 14:1991-1994
17. 17. Kirchweger R, Zeillinger R, Schneeberger C, Speiser P, Louason G, Theillet C (1994) Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. Int J Cancer 56:193-199
18. 18. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 90:4961-4965
19. 19. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984
20. 20. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS (1995) Somatic mutations in the BRCA1 in sporadic ovarian tumours. Nat Genet 9:439-443
21. 21. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
22. 22. Polymeropoulos MH, Rath DS, Xiao H, Merrill CR (1991) A simple sequence repeat polymorphism at the human growth hormone locus. Nucl Acids Res 3:689
23. 23. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y (1993) Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 53:3382-3385
24. 24. Seidman JD, Frisman DM, Norris HJ (1992) Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer 70:2857-2860
25. 25. Seizinger BR, Klinger HP, Junien C, Nakamura Y, Le Beau M, Cavanee W, Emanuel B, Ponder B, Naylor S, Mitelman F, Louis D, Menon A, Newsham I, Decker J, Kaelbling M, Henry I, v Deimling A (1991) Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 58:1080-1096
26. 26. Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, Kiang DT, Strickler JG (1992) Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23:1141-1150
27. 27. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
28. 28. Thiele M, Hartmann S, Scherthan H, Arnold W, Deppert W, Frege R, Glaab F, Haensch W, Scherneck S (1995) Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Oncogene 10:439-447
29. 29. Yang-Feng TL, Han H, Chen KC, Li SB, Claus EB, Carcangiu ML, Chambers SK, Chambers JT, Schwartz PE (1993) Allelic loss in ovarian cancer. Int J Cancer 54:546-551